Stock TQR BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited Deutsche Boerse AG

Equities

TQR

HK0000145638

Market Closed - Deutsche Boerse AG
Other stock markets
 02:04:07 2024-06-21 am EDT 		5-day change 1st Jan Change
1.07 EUR -3.60% Intraday chart for Beijing Tong Ren Tang Chinese Medicine Company Limited -2.73% -23.02%
Jun. 07 Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023 CI
May. 13 Tong Ren Tang Chinese Medicine Appoints CEO MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 11.75 for the current year.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED Stock Beijing Tong Ren Tang Chinese Medicine Company Limited
-23.02% 977M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.63% 796B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.51% 628B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.95% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.66% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+3.39% 228B
A+
NOVARTIS AG Stock Novartis AG
+10.75% 214B
B-
AMGEN INC. Stock Amgen Inc.
+6.99% 165B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 3613 Stock
  4. TQR Stock
  5. Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited